After booster vaccination, all HCW and 90% of IBD patients (85% with anti-TNF therapies, 95% with ustekinumab/vedolizumab, and 100% with other IBD medications) showed neutralizing activity against Omicron BA.1 (Figure 2C,D). This evidence concerns the gene TNF and inflammatory bowel disease.